Selection of breast cancer patients for an aromatase inhibitor after radiation and tamoxifen

被引：0
|
作者：
Freedman, GM [1 ]
Anderson, P [1 ]
Li, T [1 ]
Ross, E [1 ]
Swaby, R [1 ]
Goldstein, L [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2005年 / 63卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2005.07.413
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2019
引用
收藏
页码：S242 / S242
页数：1
相关论文
共 50 条
  • [11] Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model
    Long, BJ
    Jelovac, D
    Handratta, V
    Thiantanawat, A
    MacPherson, N
    Ragaz, J
    Goloubeva, OG
    Brodie, AM
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (06): : 456 - 465
  • [12] Switching to aromatase inhibitor (AI) after tamoxifen in premenopausal patients with chemotherapy-induced amenorrhea (CIA) after early breast cancer treatment
    Perez-Fidalgo, J. A.
    Miranda, M. J.
    Bermejo, B.
    Pons, V.
    Rosello, S.
    Garcia-Garre, E.
    Guzman, C.
    Lluch, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [13] Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer
    Harper-Wynne, CL
    Sacks, NPM
    Shenton, K
    MacNeill, FA
    Sauven, P
    Laidlaw, IJ
    Rayter, Z
    Miall, S
    Howes, A
    Salter, J
    Hills, MJ
    Lowe, FM
    A'Hern, R
    Nasiri, N
    Doody, D
    Iqbal, J
    Dowsett, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) : 1026 - 1035
  • [14] Tamoxifen or aromatase inhibitors: Should smoking status impact on selection of endocrine therapy in breast cancer patients?
    Jernstrom, H.
    Persson, M.
    Simonsson, M.
    Markkula, A.
    Rose, C.
    Ingvar, C.
    CANCER RESEARCH, 2016, 76
  • [15] Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer
    Gupta, Tanya
    Purington, Natasha
    Liu, Mina
    Han, Summer
    Sledge, George
    Schapira, Lidia
    Kurian, Allison W.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 196 (01) : 175 - 183
  • [16] Rivizor - A new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure
    Goss, PE
    Walde, D
    De Coster, R
    Langenaeken, C
    Bruynseels, J
    ONCOLOGY, 1999, 56 (02) : 114 - 121
  • [17] Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer
    Tanya Gupta
    Natasha Purington
    Mina Liu
    Summer Han
    George Sledge
    Lidia Schapira
    Allison W. Kurian
    Breast Cancer Research and Treatment, 2022, 196 : 175 - 183
  • [18] Breast cancer: Aromatase inhibitors take on tamoxifen
    Dowsett, M
    Howell, A
    NATURE MEDICINE, 2002, 8 (12) : 1341 - 1344
  • [19] Personalizing aromatase inhibitor therapy in patients with breast cancer
    Hamadeh, Issam S.
    Patel, Jai N.
    Rusin, Stephanie
    Tan, Antoinette R.
    CANCER TREATMENT REVIEWS, 2018, 70 : 47 - 55
  • [20] Effect of a switch of aromatase inhibitors to another aromatase inhibitor or tamoxifen on musculoskeletal symptoms in breast cancer; Which is the best?
    Altundag, Kadri
    JOURNAL OF BUON, 2020, 25 (04): : 2132 - 2133
12345